• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Mana Capital Acquisition Corp.

    11/22/23 4:25:49 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials
    Get the next $MAAQ alert in real time by email
    DEFA14A 1 cdio_defa14a.htm DEFINITIVE 14A ADDIONAL MATERIALS

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (RULE 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT
    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒ 

    Filed by a Party other than the Registrant ☐

     

     

    Check the appropriate box:

         
    ☐   Preliminary Proxy Statement
       
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐   Definitive Proxy Statement
       
    ☒   Definitive Additional Materials
       
    ☐   Soliciting Material Pursuant to §240.14a-12

     

    CARDIO DIAGNOSTICS HOLDINGS, INC.

    (Name of Registrant as Specified in its Certificate of Incorporation)

     

    NOT APPLICABLE

    (Name of Person(s) Filing Proxy Statement, if other than Registrant)

     

     

    Payment of Filing Fee (Check the appropriate box):

       
    ☒   No fee required.
       
    ☐   Fee paid previously with preliminary materials.
       
    ☐  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     
     

     

    SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING
    OF STOCKHOLDERS OF CARDIO DIAGNOSTICS HOLDINGS, INC.

    ANNUAL MEETING POSTPONED TO MONDAY, DECEMBER 18, 2023
    AT 1:00 P.M. CENTRAL STANDARD TIME

    The following information supplements and amends the proxy statement (“Proxy Statement”) and Notice of Annual Meeting of Stockholders (“Notice”) of Cardio Diagnostics Holdings, Inc. (the “Company”) filed with the Securities and Exchange Commission on October 27, 2023 and furnished to stockholders of the Company in connection with the solicitation of proxies by the Board of Directors of the Company (the “Board”) for the 2023 Annual Meeting of Stockholders of the Company (the “Annual Meeting”). Capitalized terms used in this supplement, dated November 22, 2023, to the Proxy Statement (this “Supplement”) and not otherwise defined herein have the meaning given to them in the Proxy Statement.

    The Board resolved to postpone the Annual Meeting previously scheduled to be held on December 4, 2023 including for the purposes of mailing an accompanying Annual Report on Form 10-K, which the Company filed on March 31, 2023, to the stockholders of the Company as of the record date of October 26, 2023. The postponed Annual Meeting will be held at 1:00 p.m. Central Standard Time on Monday, December 18, 2023. The annual meeting will be a completely “virtual” meeting. For information on how to attend the postponed Annual Meeting, please see the information in the Proxy Statement.

    The Record Date for determining stockholders eligible to vote at the Annual Meeting remains October 26, 2023. During the period of postponement, the Company will continue to accept stockholder votes and any stockholders who have not yet voted are encouraged to do so. The Company encourages any eligible stockholder that has not yet voted their shares or provided voting instructions to their broker or other record holders to do so promptly. Any stockholders who have already voted or submitted a proxy do not need to take any further action unless they wish to change their vote.

    The Proxy Statement is hereby supplemented and amended as follows:

    The following text replaces, in its entirety, the text on page 5 of the Proxy Statement for the below captioned question and answer:

    What are “broker non-votes”?

    Broker non-votes occur when a beneficial owner of shares held in “street name” does not give instructions to the broker, bank, or other nominee holding the shares as to how to vote on “non-routine” proposals. If shares are held in street name, the beneficial owner of the shares is entitled to give voting instructions to the broker, bank, or other nominee holding the shares. If the beneficial owner does not provide voting instructions, the broker, bank, or other nominee can still vote the shares with respect to matters that are “routine” under applicable rules but cannot vote the shares with respect to “non-routine” matters. On non-routine proposals, any “uninstructed shares” may not be voted by the broker, bank, or other nominee and are “broker non-votes.” The proposal to ratify the appointment of our independent registered public accounting firm and the reverse stock split proposal are considered “routine” matters for this purpose and brokers, banks, or other nominees generally have discretionary voting power with respect to such proposal. Brokers, banks, and other nominees do not have authority to vote on the election of directors or the issuance proposal without voting instruction from the beneficial owner. Broker non-votes will be counted to determine if a quorum is present at the Annual Meeting.

    The following text replaces, in its entirety, the text on page 7 of the Proxy Statement for the below captioned question and answer:

    When are other proposals and stockholder nominations for the 2024 Annual Meeting due?

    With respect to proposals and nominations not to be included in our Proxy Statement pursuant to Rule 14a-8 of the Exchange Act, our Bylaws (our “Bylaws”) provide that stockholders who wish to nominate a director or propose other business to be brought before the stockholders at an annual meeting of stockholders must notify our Secretary by a written notice, which notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the anniversary date of the immediately preceding year’s annual meeting of stockholders.

     
     

    Stockholders wishing to present nominations for director or proposals for consideration at the 2024 Annual Meeting under these provisions of our Bylaws must submit their nominations or proposals so that they are received at our principal executive offices not earlier than August 20, 2024 and not later than September 19, 2024 to be considered. In the event that the 2024 Annual Meeting is to be held on a date that is not within 30 days before or 60 days after the one-year anniversary of this Annual Meeting, then a stockholder’s notice must be received by the Secretary no later than 90 days prior to such annual meeting, or if later, the tenth day following the day on which we make a public announcement of the date of the 2024 Annual Meeting. In addition to satisfying the foregoing requirements, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Board’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than October 19, 2024.

    Nominations or proposals should be sent in writing to our Corporate Secretary at 311 West Superior Street, Suite 444, Chicago, IL 60654. A stockholder’s notice to nominate a director or bring any other business before the Annual Meeting or the 2024 Annual Meeting must set forth certain information, which is specified in our Bylaws.

    The following text replaces, in its entirety, the second paragraph under the caption “Stockholder Proposals and Nominations to be Presented at the Next Annual Meeting” on page 46 of the Proxy Statement:

    Our bylaws also provide for separate notice procedures to recommend a person for nomination as a director. To be considered timely, the stockholder’s notice must be delivered to our secretary at our principal executive offices at the address set forth above (i) in the case of an annual meeting, not later than the close of business on the 90th day nor earlier than the close of business on the 120th day before the anniversary date of the immediately preceding annual meeting of stockholders; provided, however, that in the event that the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so received not earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting was first made by us; and (ii) in the case of an annual meeting of stockholders called for the purpose of electing directors, not later than the close of business on the 10th day following the day on which public announcement of the date of the annual meeting is first made by us. The stockholder’s notice must contain the information specified in Section 3.2(d) of our bylaws, which specifies the information required to be included in the notice in order to properly propose a person to be nominated to serve as a director.

    The enclosed proxy card replaces, in its entirety, the proxy card in the Proxy Statement.

    Except as set forth herein, no additional changes have been made to the Proxy Statement or Notice or the proposals to be brought before the 2023 Annual Meeting, which are presented in the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement and Notice.

     

     
     

     

    A close-up of a document

Description automatically generated

     
     

    Close-up of a document

Description automatically generated

     

     

     

     

     

     

     

     

     

     

    Get the next $MAAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MAAQ

    DatePrice TargetRatingAnalyst
    9/2/2022$14.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $MAAQ
    SEC Filings

    View All

    Mana Capital Acquisition Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/2/24 5:02:41 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    SEC Form EFFECT filed by Mana Capital Acquisition Corp.

    EFFECT - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/2/24 12:15:12 AM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    SEC Form 424B5 filed by Mana Capital Acquisition Corp.

    424B5 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/1/24 5:00:23 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    $MAAQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mana Capital Acquisition Corp. Announces Effectiveness of Registration Statement and October 25, 2022 Special Meeting of Stockholders to Approve Business Combination with Cardio Diagnostics, Inc.

    Mana Capital Acquisition Corp. ("Mana Capital") (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))), a publicly traded special purpose acquisition company, today announced that its registration statement on Form S-4, relating to the previously announced business combination between Mana Capital and Cardio Diagnostics, Inc. ("Cardio"), a pioneering precision cardiovascular testing company, has been declared effective by the U.S. Securities and Exchange Commission. Mana Capital has mailed the definitive proxy statement/prospectus (the "Proxy Statement") to stockholders of record as of the close of business on September 27, 2022. The Proxy Statement contains a notice and voting instruction form or a proxy ca

    10/10/22 9:15:00 AM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    Mana Capital Acquisition Corp. Confirms Second Contribution to Trust Account to Extend Time Period to Complete a Business Combination

    Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital"), a special purpose acquisition company ("Mana Capital"), announced today that for the purpose of consummating its previously announced business combination with Cardio Diagnostics, Inc. ("Cardio"), the Company has further extended the date by which it is required to complete a business combination for an additional period of one (1) month from September 26, 2022 to October 26, 2022, and that the amount of $216,667 has been deposited into the Company's trust account (the "Trust Account") in connection with the extension. The funds deposited into the Trust Account were provided by Cardio unde

    9/23/22 4:15:00 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    Mana Capital Acquisition Corp. Announces Intention to Further Extend Period to Consummate Initial Business Combination

    Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital") today announced that its Board of Directors has approved a second extension of the period of time available to the Company to consummate its initial business combination by one month from September 26, 2022 to October 26, 2022 (the "Extension"), as permitted under the Company's amended and restated certificate of incorporation. In connection therewith, pursuant to the merger agreement, dated May 27, 2022, among the Company, Mana Merger Sub, Inc., Cardio Diagnostics, Inc. ("Cardio"), and Meeshanthini (Meesha) Dogan, as representative of the shareholders of Cardio, Cardio is expected to depo

    9/22/22 4:15:00 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    $MAAQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Mana Capital Acquisition Corp. with a new price target

    The Benchmark Company initiated coverage of Mana Capital Acquisition Corp. with a rating of Speculative Buy and set a new price target of $14.00

    9/2/22 9:04:13 AM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    $MAAQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mana Capital Acquisition Corp.

    SC 13G - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

    2/2/24 3:57:30 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13D/A filed by Mana Capital Acquisition Corp. (Amendment)

    SC 13D/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

    6/28/23 2:51:40 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13D/A filed by Mana Capital Acquisition Corp. (Amendment)

    SC 13D/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

    6/28/23 2:17:18 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    $MAAQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lau Stanley K. exercised 917 shares at a strike of $2.18, increasing direct ownership by 1% to 91,522 units (SEC Form 4)

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    2/5/24 4:50:57 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    SEC Form 3 filed by new insider Burton Paul Frederick

    3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    1/4/24 2:07:56 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials

    Levy Oded exercised 5,020 shares at a strike of $2.49, increasing direct ownership by 9% to 62,793 units (SEC Form 4) (Amendment)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    1/2/24 6:10:14 PM ET
    $MAAQ
    Consumer Electronics/Appliances
    Industrials